Monoclonal antibody 2A11

Drug Profile

Monoclonal antibody 2A11

Latest Information Update: 20 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Nonindustrial source
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Small cell lung cancer

Most Recent Events

  • 20 Jul 2006 No development reported - Phase-II for Small cell lung cancer in USA (IV-infusion)
  • 16 Feb 2000 A phase I trial in lung cancer has been added to the therapeutic trials and pharmacokinetics sections
  • 23 Jul 1997 Phase-II clinical trials for Small cell lung cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top